Douglas A. Treco - 11 Mar 2025 Form 4 Insider Report for Inozyme Pharma, Inc. (INZY)

Role
CEO, Director
Signature
/s/ Sanjay Subramanian, as attorney-in-fact for Douglas A Treco
Issuer symbol
INZY
Transactions as of
11 Mar 2025
Net transactions value
$0
Form type
4
Filing time
17 Mar 2025, 16:24:07 UTC
Previous filing
03 Oct 2024
Next filing
03 Apr 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INZY Stock Option (right to buy) Award $0 +400,000 $0.000000 400,000 11 Mar 2025 Common Stock 400,000 $1.06 Direct F1, F2
transaction INZY Restricted Stock Units Award $0 +100,000 $0.000000 100,000 11 Mar 2025 Common Stock 100,000 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The exercise price represents the closing price of the Issuer's common stock on March 11, 2025.
F2 The option was granted on March 11, 2025 and is scheduled to vest in equal monthly installments until the fourth anniversary of the grant date.
F3 The restricted stock units were granted on March 11, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. 33% of the restricted stock units vest on March 11, 2026, with the remaining 67% vesting in eight equal quarterly installments thereafter, such that the restricted stock units will be fully vested on March 11, 2028.